Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Paclitaxel 7Cisplatin 6pembrolizumab 5Carboplatin 5Bevacizumab 5liposomal doxorubicin 3Gemcitabine 3trebananib 2niraparib 2interferon gamma-1b 2dostarlimab 2catumaxomab 2atezolizumab 2anlotinib 2Topotecan 2Radiotherapy, Intensity-Modulated 2Ocoxin 2Itraconazole 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Docetaxel 2vosaroxin 1vistusertib 1pertuzumab 1peginterferon alfa-2b 1olaparib 1nintedanib 1lanreotide 1epothilone B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × peginterferon alfa-2b × Gynecologic × Clear all
NCT02948426 2026-01-08

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
18 enrolled 19 charts
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡